1. Clinicopathological and prognostic significance of metastasis-associated protein 1 expression and its correlation with angiogenesis in lung invasive adenocarcinomas, based on the 2011 IASLC/ATS/ERS classification
- Author
-
Wensi Hu, Cun Gao, Hui Tian, Ming Lu, Weiming Yue, Guanqing Chen, Chuanle Cheng, Shuhai Li, Lin Li, Jingjing Cui, Lei Qi, and Libo Si
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Pathology ,metastasis-associated protein 1 ,Metastasis ,03 medical and health sciences ,angiogenesis ,0302 clinical medicine ,microvessel density ,Internal medicine ,medicine ,Lung cancer ,Survival analysis ,Lung ,Oncogene ,business.industry ,Cancer ,Articles ,medicine.disease ,Molecular medicine ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Adenocarcinoma ,prognosis ,lung invasive adenocarcinoma ,business - Abstract
Based on previous findings regarding the angiogenic activities and prognostic roles of metastasis-associated protein 1 (MTA1) in early-stage non-small cell lung cancer, the clinicopathological and prognostic significance of MTA1 protein expression, and its correlation with angiogenesis in lung invasive adenocarcinoma, were further assessed in the present study, according to the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. High protein expression levels of MTA1 were commonly observed in patients with lung invasive adenocarcinoma, and were significantly correlated with tumor size (P=0.030), lymph node metastasis (P=0.021) and microvessel density (P=0.015). Survival analysis demonstrated that patients with high protein expression levels of MTA1 exhibited significantly shorter five-year disease-free and overall survival than those patients whose protein expression levels of MTA1 were low (24.5% vs. 48.7%, P=0.001, and 34.7% vs. 59.2%, P=0.005, respectively). In addition, Cox regression multivariate analysis demonstrated that high protein expression levels of MTA1 significantly correlated with unfavorable five-year disease-free survival (P=0.024). These findings indicate that MTA1 protein expression may possess clinical potential as an indicator of progressive phenotype. Therefore, MTA1 is a promising prognostic predictor to identify subgroups of patients with high risk of relapse, and a potentially novel therapeutic target for antiangiogenesis in patients with lung invasive adenocarcinoma.
- Published
- 2014